MarketCapExport financials
Quotient Limited (QTNT)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Quotient Limited Income Statement 2022-2011 | QTNT
Brief overview of revenue and earnings at Quotient Limited
The overview follows changes across a five-year period. Revenue at Quotient Limited moved from 22.2 million dollars in 2017 to 38.5 million dollars in 2022. Overall revenue changed by +73.3%, equal to an annualized rate of about 11.6%. The pace indicates confident and sustained business growth.
The five-year change in gross profit reached +31.3%: from 11.4 million dollars to 14.9 million dollars. Direct costs outpaced revenue, limiting the benefit of changes in sales. At the margin level, the figure shifted from 51.2% to 38.8%. The business retained less gross profit from each unit of revenue.
EBITDA was −64.7 million dollars at the beginning and −96.6 million dollars at the end of the period (−49.4%). Operating performance weakened relative to revenue. EBITDA margin was −291% at the start and −250.9% at the end. The business generated more EBITDA from each unit of revenue.
Net income moved from −$85.1 million at the start to −$125 million at the end. Larger losses indicate rising pressure on the business.
What the figures show
The indicators point to a weaker financial profile. The positive side is supported by positive operating leverage and revenue expansion. The most visible risks are pressure from direct costs, a weaker final result and a low EBITDA margin. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Quotient Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | 237 M | 526 M | 522 M | 250 M | 139 M | 94.7 M | 236 M | 3.36 M | - | - | - |
Shares |
102 M | 91.6 M | 101 M | 54.9 M | 40.8 M | 28.1 M | 19.6 M | 14.8 M | 187 K | 74.9 K | - | - |
Historical Prices |
- | 2.59 | 5.21 | 9.51 | 6.12 | 4.95 | 4.84 | 16 | 18 | - | - | - |
Net Income |
-125 M | -111 M | -31.7 M | -106 M | -82.3 M | -85.1 M | -33.9 M | -59.1 M | -10.2 M | -4.71 M | -4.47 M | -4.62 M |
Revenue |
38.5 M | 43.4 M | 32.7 M | 29.1 M | 24.7 M | 22.2 M | 18.5 M | 18.4 M | 19.8 M | 14.4 M | 12.2 M | 10 M |
Cost of Revenue |
23.6 M | 20.1 M | 4.97 M | 17.2 M | 10.5 M | 10.8 M | 9.66 M | 9.76 M | 8.41 M | 7.17 M | - | - |
Gross Profit |
14.9 M | 23.3 M | 3.78 M | 11.9 M | 14.3 M | 11.4 M | 8.86 M | 8.64 M | 11.3 M | 7.2 M | 5.47 M | 4.41 M |
Operating Income |
-104 M | -82.7 M | -21.6 M | -79.2 M | -70 M | -74.1 M | -49.1 M | -29.7 M | -8.89 M | -4.49 M | - | - |
Interest Expense |
11.6 M | 2.72 M | 617 K | -6.94 M | 2.37 M | -1.11 M | 3.5 M | -4.06 M | -197 K | 11 K | - | - |
EBITDA |
-96.6 M | -73.9 M | -9.13 M | -66.5 M | -59.7 M | -64.7 M | -46.2 M | -28.5 M | -8.37 M | -4.15 M | -2.98 M | -3.12 M |
Operating Expenses |
119 M | 106 M | 25.4 M | 91.1 M | 84.2 M | 85.4 M | 58 M | 38.4 M | 20.2 M | 11.7 M | 9.43 M | 8.5 M |
General and Administrative Expenses |
42.1 M | 37.4 M | 7.52 M | 26.6 M | 21.5 M | 18.5 M | 24.1 M | 15.3 M | 8.54 M | 6.35 M | 6.01 M | 5.35 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Quotient Limited
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
4.25 M | 4.25 M | 105 M | 4.25 M | 102 M | 102 M | 101 M | 2.55 M | 101 M | 83.9 M | 80.5 M | 101 M | 73.8 M | 66.3 M | 66.1 M | 73.8 M | 56.6 M | 52.1 M | 45.8 M | 56.6 M | 56.6 M | 52.1 M | 45.6 M | 43.4 M | 43.4 M | 37.7 M | 36.8 M | 29.5 M | 20.4 M | 17.4 M | 17 M | 20.4 M | 15.1 M | 14.4 M | 12.8 M | 15.1 M | 14.4 M | 12.8 M | 342 K | 829 K | 144 K | 237 K | - | - | - | - | - | - | - | - | - |
Net Income |
-13.3 M | -45.9 M | -38.9 M | -13.3 M | -44.8 M | -27.1 M | -27.3 M | -44.8 M | -29.8 M | -15 M | -25.4 M | -31.7 M | -27.5 M | -27 M | -23.6 M | -27.5 M | -26.3 M | -27.4 M | -25.2 M | -26.3 M | -26.3 M | -27.4 M | - | -20.3 M | -20.3 M | -21.7 M | -20.2 M | -31.2 M | -9.78 M | -4.43 M | -10.2 M | -9.78 M | -42.3 M | -11.7 M | -2.62 M | -42.3 M | -56.6 M | -14.3 M | - | -3.27 M | -4.95 M | -1.68 M | - | - | - | - | - | - | - | - | - |
Revenue |
9.95 M | 8.86 M | 8.81 M | 9.95 M | 10.2 M | 9.47 M | 9.09 M | 10.2 M | 8.75 M | 16.1 M | 8.92 M | 8.75 M | 7.94 M | 7.85 M | 8.17 M | 7.94 M | 6.72 M | 6.25 M | 7.88 M | 6.72 M | 6.72 M | 6.25 M | - | 5.86 M | 5.86 M | 5.91 M | 6.83 M | 4.84 M | 4.35 M | 4.27 M | 4.85 M | 4.35 M | 4.06 M | 4.53 M | 5.92 M | 4.06 M | 14.5 M | 10.4 M | - | 3.91 M | 15.1 M | 11.2 M | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
3.9 M | 21.1 M | 6.12 M | 3.9 M | 7.93 M | 4.88 M | 4.78 M | 7.93 M | 4.97 M | 4.5 M | 5.41 M | 4.97 M | 4.53 M | 3.97 M | 4.56 M | 4.53 M | 4.19 M | 4.55 M | 4.06 M | 4.19 M | 4.19 M | 4.55 M | - | 2.32 M | 2.32 M | 2.79 M | 2.83 M | 2.6 M | 2.22 M | 2.12 M | 2.75 M | 2.22 M | 2.2 M | 2.71 M | 2.45 M | 2.2 M | 7.36 M | 5.16 M | - | 1.94 M | 6.27 M | 4.33 M | - | - | - | - | - | - | - | - | - |
Gross Profit |
6.05 M | -12.3 M | 2.69 M | 6.05 M | 2.24 M | 4.59 M | 4.31 M | 2.24 M | 3.78 M | 11.6 M | 3.51 M | 3.78 M | 3.41 M | 3.88 M | 3.61 M | 3.41 M | 2.54 M | 1.7 M | 3.82 M | 2.54 M | 2.54 M | 1.7 M | - | 3.53 M | 3.53 M | 3.12 M | 3.99 M | 2.24 M | 2.13 M | 2.15 M | 2.1 M | 2.13 M | 1.86 M | 1.82 M | 3.47 M | 1.86 M | 7.14 M | 5.29 M | - | 1.97 M | 8.83 M | 6.86 M | - | - | - | - | - | - | - | - | - |
Operating Income |
-25.6 M | -37.7 M | -25.8 M | -25.6 M | -31.3 M | -23.8 M | -21.9 M | -31.3 M | -21.7 M | -13.1 M | -19.7 M | -21.6 M | -22.4 M | -18.4 M | -18.4 M | -22.4 M | -19 M | -21.1 M | -18.5 M | -19 M | -19 M | -21.1 M | - | -17.1 M | -17.1 M | -18.1 M | -16.9 M | -22.4 M | -12.8 M | -13 M | -10.5 M | -12.8 M | -7.33 M | -8.22 M | -4.41 M | -7.33 M | -20 M | -12.6 M | - | -2.8 M | -4.29 M | -1.49 M | - | - | - | - | - | - | - | - | - |
Interest Expense |
20.6 M | -15.2 M | -4.37 M | 20.6 M | -3.51 M | 5.92 M | 9.5 M | -3.51 M | 192 K | 5 M | 233 K | 617 K | 1.89 M | -1.24 M | 952 K | 1.89 M | -1.54 M | -468 K | -3.51 M | -1.54 M | -1.54 M | -468 K | - | 33 K | 33 K | 565 K | 880 K | -4.57 M | 305 K | -657 K | -635 K | 305 K | 130 K | -2.96 M | 534 K | 130 K | -1.49 M | 534 K | - | -45 K | -83 K | 77 K | - | - | - | - | - | - | - | - | - |
EBITDA |
-25.6 M | -37.7 M | -25.8 M | -25.6 M | -31.3 M | -23.8 M | -21.9 M | -31.3 M | -19.4 M | -10.9 M | -17.8 M | -19.2 M | -13.4 M | -12.4 M | -15.4 M | -19.5 M | -9.52 M | -14.6 M | -15.2 M | -16 M | -9.52 M | -14.6 M | - | -14.5 M | -9.42 M | -13 M | -14.4 M | -20.1 M | -11.2 M | -12.1 M | -10.1 M | -12.1 M | -6.39 M | -7.62 M | -4.12 M | -7.01 M | -19 M | -12.3 M | - | -2.8 M | -3.91 M | -1.25 M | - | - | - | - | - | - | - | - | - |
Operating Expenses |
31.6 M | 25.5 M | 28.5 M | 31.6 M | 33.5 M | 28.4 M | 26.2 M | 33.5 M | 25.5 M | 24.7 M | 23.2 M | 25.4 M | 25.8 M | 22.3 M | 22 M | 25.8 M | 21.6 M | 22.8 M | 22.4 M | 21.6 M | 21.6 M | 22.8 M | - | 20.6 M | 20.6 M | 21.2 M | 20.9 M | 24.7 M | 14.9 M | 15.1 M | 12.6 M | 14.9 M | 9.18 M | 10 M | 7.87 M | 9.18 M | 27.1 M | 17.9 M | - | 4.77 M | 13.1 M | 8.35 M | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
11.5 M | 7.66 M | 9.4 M | 11.5 M | 15 M | 8.62 M | 8.35 M | 15 M | 7.52 M | 8.23 M | 8.58 M | 7.52 M | 8.12 M | 5.98 M | 6.62 M | 8.12 M | 6.47 M | 6.76 M | 6.16 M | 6.47 M | 6.47 M | 6.76 M | - | 5.8 M | 5.8 M | 4.79 M | 5.26 M | 4.54 M | 6.49 M | 5.49 M | 4.79 M | 6.49 M | 3.64 M | 3.72 M | 3.26 M | 3.64 M | 10.6 M | 6.98 M | - | 1.96 M | 5.44 M | 3.49 M | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Quotient Limited (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K |  USA |
 |
Biomerica
BMRA
|
$ 1.71 | -0.51 % | $ 4.98 M | USA |
 |
Myriad Genetics
MYGN
|
$ 5.57 | 0.54 % | $ 516 M | USA |
 |
Pacific Biosciences of California
PACB
|
$ 2.14 | 9.18 % | $ 642 M | USA |
 |
Neuronetics
STIM
|
$ 2.01 | 1.52 % | $ 133 M | USA |
 |
Agilent Technologies
A
|
$ 177.75 | 2.74 % | $ 50.5 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 344.87 | 9.31 % | $ 17.1 B | USA |
 |
Biodesix
BDSX
|
$ 23.93 | 0.25 % | $ 181 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 13.51 | 6.71 % | $ 142 M |  China |
 |
Bioventus
BVS
|
$ 14.24 | 2.08 % | $ 949 M | USA |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
CareDx, Inc
CDNA
|
$ 70.74 | 2.23 % | $ 3.77 B | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Co-Diagnostics
CODX
|
$ 0.64 | -0.82 % | $ 851 K | USA |
 |
Danaher Corporation
DHR
|
$ 233.86 | 4.32 % | $ 167 B | USA |
 |
Fulgent Genetics
FLGT
|
$ 20.13 | -0.98 % | $ 620 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
IQVIA Holdings
IQV
|
$ 276.63 | 3.28 % | $ 47.6 B | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 323.75 | 0.19 % | $ 26.9 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 2.71 | 1.12 % | $ 88 K | USA |
 |
Lantheus Holdings
LNTH
|
$ 100.24 | -0.15 % | $ 6.77 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
Celcuity
CELC
|
$ 61.56 | 2.6 % | $ 2.88 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Medpace Holdings
MEDP
|
$ 662.48 | 6.43 % | $ 19.1 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 677.94 | 2.69 % | $ 34.6 B |  Schweiz |
 |
NeoGenomics
NEO
|
$ 17.04 | 2.53 % | $ 2.18 B | USA |
 |
Neogen Corporation
NEOG
|
$ 11.79 | 0.6 % | $ 2.56 B | USA |
 |
National Research Corporation
NRC
|
$ 20.31 | -1.84 % | $ 455 M | USA |
 |
Brainsway Ltd.
BWAY
|
$ 11.98 | -0.42 % | $ 407 M | Israel |
 |
Koninklijke Philips N.V.
PHG
|
$ 26.23 | 0.85 % | $ 24.9 B |  Niderland |
 |
Precipio
PRPO
|
$ 21.25 | -2.16 % | $ 34.1 M | USA |
 |
Castle Biosciences
CSTL
|
$ 34.37 | 3.68 % | $ 996 M | USA |
 |
Guardant Health
GH
|
$ 166.66 | 2.5 % | $ 20.9 B | USA |
 |
RadNet
RDNT
|
$ 68.41 | -1.78 % | $ 5.14 B | USA |
 |
DarioHealth Corp.
DRIO
|
$ 3.68 | -9.8 % | $ 14.7 M | Israel |
 |
DexCom
DXCM
|
$ 80.26 | -6.39 % | $ 31.3 B | USA |
 |
Senseonics Holdings
SENS
|
$ 7.97 | -2.92 % | $ 333 M | USA |
 |
Illumina
ILMN
|
$ 282.86 | 5.57 % | $ 43.8 B | USA |